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In English
The impact of written information about 
medicinal products is limited
The big issue on the mind of the producer and sup-
plier of information about medicinal products is
whether the information reaches its target and what
impact does it have? This is a relevant question irre-
spective of whether the recipient of the information
is a health care professional or a consumer who
needs the product. The basic starting point in Eu-
rope is for the pharmaceutical industry to produce
written summaries of product characteristics (for
health care professionals) and patient information
leaflets (for patients) concerning their medicinal
products, followed by approval from the  regulatory
authorities. There is, however, limited knowledge
about the effectiveness of these or of any other writ-
ten information.
Newly published information about the relevance
and impact of written drug information to the pa-
tient is now available, based on the evaluation of ex-
tensive research data and on patients’ own views.1
The main observation made by British researchers
was that most people do not appreciate the written
information they receive about medicinal products.
There appears to be a gap of some magnitude be-
tween the written information and the information
actually valued and experienced as something useful
by patients. Patients prefer information tailored to
their own needs and revealing both benefits and
harmful effects of treatments with pharmaceuticals.
Information about harmful effects of medicinal
products are still considered very important and
they ought to be based on numerical assessments
rather than on verbal risk evaluations. 
Even though the significance of the quality and
readability of the written information is emphasised
by researchers, preference is predominantly given to
the verbal information delivered by health care pro-
fessionals. Written information about medicines
should not replace a discussion with a professional. 
It is well known that Finns have great faith in the
written word. The results of the study made in the
UK can therefore hardly be generalised as such to
the situation in Finland. It is a different matter
whether texts are understood in the way they are in-
tended to be understood even though they were in
fact believed.
In April the European Commission published a
draft report2 in which, among other things, the prac-
tices of different countries are reviewed with regard
to the provision of information to patients about
diseases and their medication. Based on the final re-
port the Commission will consider any proposals for
a strategy for future information about medicines.
New models of operation may have to be considered
with the Internet as a channel for information and
the role of the pharmaceutical industry associated
with it.
Information about medicinal products is to an in-
creasing degree searched for on the Internet, and the
significance of the Internet in the acquisition of this
information is likely to increase.3 Reliable informa-
tion should also be available on the Internet for the
consumer. Whose task is it to satisfy this need – is it
that of the authorities, the public health care organi-
sations, the professional bodies and the scientific
community, or of the pharmaceutical industry? Or
should we just rely on it, that consumers are capable
of evaluating critically any information about medic-
inal products published on the Internet? Drawing
the line in pharmaceutical marketing is nevertheless
clear. Advertising of prescription drugs to the public
is prohibited, and if the consumer bodies in Finland
were asked, a preference for also preserving it in fu-
ture would prevail.4 Moreover, nowhere in Europe is
there any declared support for the advertising of
prescription medicines to the public.
If a new role be proposed for or recommended to
the pharmaceutical industry, involving the provision
of drug information about diseases and prescription
drugs also to consumers, the challenges involved are
great. In that case, the responsibility for supplying
information about medicinal products would be
shifted towards the pharmaceutical industry. 
Whether we are ready for this in Europe remains
to be seen. It is not only a question of producing
and providing the information as such, but also one
of the interaction between the consumer and the
pharmaceutical industry in general. 
1 Raynor DK, Blenkinsopp A, Knapp P, Grime J, et al. A system-
atic review of quantitative and qualitative research on the role
and effectiveness of written information available to patients
about individual medicines. Health Technol Assess 2007;11(5). 
2 Draft report on current practice with regard to provision of in-
formation to patients on medicinal products, EC 19 April 2007.
3 Närhi U. Internet suomalaisten lääketiedon lähteenä (Internet
as the source of drug information for Finns). TABU. 3.2007, 8-
10.
4 The Finnish Consumers’ Association: Ei reseptilääkkeiden
mainontaa kuluttajille (No advertising of prescription drugs to
the consumer). Press release of 21.6.2007.
Hannes Wahlroos
Professor, Director General
National Agency for Medicines
Editorial
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The medicines treatment of tuberculosis, 
a challenge for the patient and the health care staff
Tuberculosis (TB) is the most fa-
tal infectious disease after AIDS
in the world. Drug resistant
strains are, for example, a prob-
lem in Russia and the Baltic
countries.
The epidemiological situation
in Finland is good, but as the
disease is becoming rarer it is
posing ever-increasing challenges.
The number of new cases in
2006 was for the first time be-
low 300,  while the prevalence
was 5.6 per 100,000 inhabitants.
Consequently, health care centre 
personnel in Finland do not nec-
essarily even see a patient with
tuberculosis every year. We
should bear in mind the possibil-
ity of tuberculosis, however,
when patients attending the ap-
pointment belong to a risk group
(e.g. the elderly, intoxicant
abusers, immigrants from coun-
tries with high prevalence of TB
and close contacts with TB pa-
tients) and present with symp-
toms. Early suspicion of a dis-
ease and directing the patient for
examinations and therapy are es-
sential for preventing the spread
of the disease.
The treatment of elderly pa-
tients with multiple diseases and
of abusers has become a particu-
lar challenge. According to a
Finnish study investigating the fi-
nal outcome of treatment in tu-
berculosis, there are great varia-
tions in the combinations of
drugs used and the duration of
the courses of treatment (1). The
final outcome of treatment has
been good, according to the
WHO criteria, in 65% of the
study subjects suffering from pul-
monary tuberculosis confirmed
by cultivation (according to mi-
crobiological criteria, the disease
was healed and the treatment
was concluded while the clinical
response was good) (2). The
knowledge and skills for treat-
ment possessed by the care staff,
together with immigration move-
ment from countries of high
prevalence, are decisive for keep-
ing the present epidemiological
situation in control in the future.
A book on the National tubercu-
losis treatment programme was
published last year by the Min-
istry of Social Affairs and Health
in Finland (3).  
Principles of medications
Tuberculosis is a reportable con-
tagious disease, with free treat-
ment for patients. The treatment
principles for tuberculosis differ
from those for other microbial
diseases. A build-up of resistance
to the few basic drugs develops
relatively rapidly and a combina-
tion of drugs ought therefore al-
ways to be used in the treatment
of any disease caused by My-
cobacterium  tuberculosis. In ad-
dition, the treatment should last
for months. There are five prima-
ry drugs for the treatment of tu-
berculosis:  isoniazide (INH), rif-
ampicin (RIF), pyrazinamide
(PZA), ethambutol (EMB) and
streptomycin (SM).  
Mycobacteria enter the cells,
and their destruction consequent-
ly also requires effective cell-me-
diated immunity. The lipid wall
of the tuberculosis bacterium is
an effective protection against
immune defence and antimicro-
bial drugs. The thick bacterial
wall containing mycolic acids al-
so protects against the cytolytic
effects of phagocytes. The bac-
terium is also capable of synthe-
tisizing enzymes able to degrade
drugs (4). The primary drugs are
bactericidal, except for ethambu-
tol. Their mechanisms of action
differ from one to another, in
that isoniazide is able to quickly
destroy actively dividing bacte-
ria, and rifampicin is at its best
against mycobacteria which re-
produce in stages. Isoniazide and
rifampicin together form the ba-
sis of the treatment; their combi-
nation should always be used
during the entire course of treat-
ment, unless restricted by adverse
reactions. 
The standard duration of
treatment is six months (Table
1). The treatment is initiated by
an intensive stage lasting for 2
months, during which pyrazin-
amide is also used adjunctively
with isoniazide and rifampicin.
In situations where there is cause
to suspect drug-resistant tubercu-
losis, or where the disease has re-
curred, all five primary drugs
should be used concomitantly.
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The total duration of treatment is
then prolonged, even up to 12
months. Adding one drug at a
time to an ineffective combina-
tion of drugs is malpractice and
may rapidly lead to the develop-
ment of resistance.
If the suspected cause of the
disease is a multi-drug resistant
(MDR) or an extensively drug re-
sistant (XDR) strain, gene testing
for rifampicin and isoniazide re-
sistance on the patient’s sputum
sample should be requested from
the laboratory for mycobacterial
testing at the National Public
Health Institute in Finland.
Drug treatment should be
planned individually, based on
the patient’s background data
and the drug sensitivity data for
the possible source of the infec-
tion. In these patients the treat-
ment will last for about two
years. More details about the
treatment of drug resistant tuber-
culosis is available at:
http://whqlibdoc.who.int/publica-
tions/2006/9241546956_eng.pdf.
Five primary drugs
Isoniazide is a synthetic medicinal
substance inhibiting the bacterial
wall mycolic acid metabolism. It
is orally well absorbed and an
adequate plasma concentration is
achieved within a couple of
hours, as well as equivalent levels
in the pleural and spinal cord flu-
ids. The drug causes peripheral
neuritis in some people, and pa-
tients ought therefore always also
to take vitamin B6. Rifampicin is
a semi-synthetic rifamycin deriva-
tive, which was introduced into
general use at the end of the
1960s. Its effect is bactericidal.
Rifampicin is orally quickly ab-
sorbed. Its distribution in the
body is uniform with adequate
concentrations also achieved in
tissue and infection fluids, as well
as tuberculous cavities. Its peak
blood concentration is attained
within about three hours of ad-
ministration. Isoniazide and rif-
ampicin may also be adminis-
tered intravenously. 
Pyrazinamide is a synthetic
drug which becomes active with-
in the body and is at its best in-
side the cells and in an acid envi-
ronment. It has an effect only on
the bacillus Mycobacterium tu-
berculosis and is a bactericidal
medicine, which effectively rids
the tissue of bacteria, and is
therefore important at the inten-
sive stage of the treatment. Its
oral absorption is efficient and it
is evenly distributed in the body.
Ethambutol is a bacteriostatic
medicinal substance, which is
well absorbed from the gastroin-
testinal canal, evenly distributed
in the body, and penetrates the
blood-brain barrier when inflam-
mation requires this. It is mainly
excreted unchanged in the urine.
The patients with renal insuffi-
ciency (creatinine clearance < 30
ml/min) should take ethambutol
3 times in week. 
Streptomycin in the form of
the aminoglycoside administrates
intramuscularly. It has a bacteri-
cidal effect on mycobacteria, but
the effect is low. It may quickly
lead to mycobacterial resistance
(within 1–2 months) if it is used
without the support of any other
effective TB medication. Strepto-
mycin has a low blood-brain bar-
rier penetration. It is chiefly ex-
creted in the urine, and therefore,
when the renal function is deter-
iorating the dose is reduced to
the level of 12 to 15 mg/kg and
the dose interval is increased. The
doses for the primary drugs are
shown in Table 2. 
Steroid treatment as adjunct
to tuberculosis medication?
Adequate proof of the advantage
of steroid treatment has been ob-
tained primarily in the treatment
of tubercular meningitis and peri-
carditis. Steroid treatment in
these patient groups reduces the
risk of death and may decrease
symptoms and complications.
Steroid treatment may be benefi-
cial if the patient has severe tissue
damage induced by tuberculosis,
such as advanced pulmonary tu-
berculosis and malnutrition in-
cluding excessive pleural fluid ac-
cumulation which is not cleared
by aspiration. Corticosteroids
may also be used in the treatment
of the rare IRIS reaction (immune
reconstitution inflammatory syn-
drome, i.e. a paradoxical increase
Table 1. Primary drug treatment and intensified treatment in tuberculosis 
Treatment of tuberculosis Initial treatment Follow-up treatment Duration of treatment
Primary treatment INH, RIF and PZA  2 months INH and RIF  4 months 6 months1
Intensified treatment INH, RIF, PZA, EMB ± SM2    2 months RIF and EMB  10 months 12 months3
INH, RIF, PZA, EMB and SM   2 months
and INH, RIF, PZA and EMB   1 months INH, RIF and EMB  5 months 8 months 4
INH isoniazide, RIF rifampicin, PZA pyrazinamide, EMB ethambutol, SM streptomycin
1 In skeletal and miliary tuberculosis the total duration of treatment is 6–9 months and in meningitis 12 months
2 Suspected resistance to INH or INH and SM 
3 Resistance to INH or INH and SM confirmed
4 Disease recurred
In English
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in symptoms and findings during
therapy while the immunological
defence capacity is recovering)
and of serious drug-induced hy-
persensitivity reactions.
Monitoring of treatment is the
responsibility of specialised
care
The treatment of a contagious
patient (with a positive-staining
slide of the sputum) is initiated in
an isolation room. The isolation
treatment of a patient with drug
sensitive tuberculosis should be
continued for at least 2 weeks, af-
ter which the patient is dis-
charged from hospital, and the
first control appointment is
arranged at an outpatient clinic a
month after the start of treat-
ment. Follow-up appointments
are continued thereafter at 1 to 2
months intervals. It is recom-
mended that the introduction of
treatment in a tuberculosis pa-
tient with a negative-staining spu-
tum test should take place in an
inpatient ward when the patient
is elderly, suffering from multiple
diseases or using several other
drugs; this makes the monitoring
of the patient’s condition easier
insofar as any adverse reactions
are concerned. During inpatient
care the drug treatments are ex-
plained to the patient and his or
her compliance is assessed. 
Outpatient control appoint-
ments are aimed at monitoring
the patient’s clinical condition
and for any adverse drug reac-
tions, while the efficacy of treat-
ment is assessed with the help of
pulmonary X-rays, sputum sam-
ples and blood tests. It is recom-
mended that laboratory tests
(ALT, Bil, blood cell count and
CRP and ESR if they were elevat-
ed at the start of the treatment)
are carried out at 2 weeks’ inter-
vals during the first month, fol-
lowed by lab tests at 2 and 4
months after the start of treat-
ment unless the liver enzyme val-
ues are significantly elevated. A
pulmonary X-ray will be per-
formed after 2 months of treat-
ment and at the end of treatment.
TB bacterial staining and cultiva-
tion of the sputum samples will
be examined 2 to 5 weeks after
the initiation and at the end of
the treatment. If sputum is no
longer being produced by the pa-
tient, this will be mentioned in
the concluding evaluation. Dur-
ing ethambutol medication, in or-
der to exclude optic neuritis, un-
dergoing a monthly visual check
and a colour vision examination
should not be neglected. 
Table 2. The primary tuberculosis drug doses in adults 
Drug mg/kg/day Daily dose mg/kg x 3 / week
(maximum) (maximum)
Isoniazide 5  300 mg 15
INH (300 mg) (900 mg)
Rifampicin 10 450 mg <50 kg 10
RIF (600 mg) 600 mg >50 kg (600 mg)
Pyrazinamide 20–30 1000 mg <55 kg 35–40
PZA (2,000 mg) 1,500 mg 55–75 kg (3,000 mg)
2,000 mg >75 kg 
Ethambutol 15–25 800 mg <55 kg 25–30
EMB (1,600 mg) 1,200 mg 55-75 kg (2,400 mg)
1,600 mg >75 kg
Streptomycin 15 750-1,000 mg 15 1   (1,000 mg)
SM (1,000 mg)
1 The dosage x 5–7/week during the intensive period (usually 2 months), and as the treatment continues,
the dosage x 3 / week 
Table 3. Recommendations for measures in case of liver reaction due to tuberculosis medication
Liver enzyme value from the Condition of patient Continuation of tuberculosis Follow-up of laboratory values
upper limit of normal value medication (isoniazide, 
rifampicin, pyrazinamide)
ALT value < 3-fold Symptomfree Tuberculosis medication is continued ALT once in 2 weeks until value is normal
Symptoms1 Tuberculosis medication is continued ALT and Bil x 1 / week2
ALT value  > 3-fold Symptomfree Tuberculosis medication is continued ALT and Bil x 1 / week2
Symptoms3 Tuberculosis medication is interrupted ALT and Bil x 1–2 / week
Medication is continued if values
are normal and patient is symptomfree
ALT value  > 5-fold or Symptomfree or Tuberculosis medication is interrupted ALT and Bil x 1–2 / week
bilirubin level is increasing with symptoms Medication is continued if values 
are normal and patient is symptomfree
1 Lack of appetite, mild nausea or abdominal pain
2 If bilirubin is elevated, medication should be interrupted
3 Nausea, abdominal pain, vomiting, fever, jaundice or unexplained impairment of general condition
Adverse drug reactions — what
measures to take?
A relatively large proportion of
the patients treated, 5 to 33%,
suffer adverse drug reactions
from tuberculosis drugs, mostly
exhibited during the first months
of treatment (5). Elevation of he-
patic enzyme values is common
and the values may be reduced
during ongoing treatment. Moni-
toring of the laboratory results is
adequate at this stage. If more
distinct elevation of the values
and/or serious symptoms occur,
the treatment should be discon-
tinued (Table 3) (3,5). At this
point other causes for disrupting
the liver function should be re-
viewed (virus hepatitis, alcohol,
biliary duct disorder, other drugs
with liver toxicity).  
Isoniazide and rifampicin still
remain the most important tuber-
culosis drugs. Their efficacy and
adequate duration of treatment
have been the subject of several
studies. The aim is to continue
the use of these drugs unless seri-
ous adverse reactions occur. De-
pending on the situation, medica-
tions are initiated individually in-
creasing the dose as necessary
(Table 4).
A reminder of interactions
Potential interactions should al-
ways be checked when tuberculo-
sis drugs are introduced, as well
as when a new drug is prescribed
to treat another disease in a pa-
tient on tuberculosis therapy. 
Rifampicin induces many cy-
tochrome P-450 system isoen-
zymes and accelerates the elimi-
nation of drugs metabolised via
this system. This results, for ex-
ample, in reduced efficacy of
warfarin, antidiabetic agents and
diazepam, which often makes it
necessary to increase the thera-
peutic dose of these drugs. Dur-
ing rifampicin therapy it is usual-
ly necessary to double the dose of
steroids to maintain their efficacy.
Female patients should be in-
formed about the reduced effica-
cy of estrogen products and ad-
vised to change their method of
contraception. Equally, on dis-
continuation of rifampicin thera-
py (inducing effect continues for
about 2 weeks), the therapeutic
doses of the drugs above should
be reduced back to their appro-
priate level. Isoniazide inhibits
the cytochrome P-450 system
isoenzymes, and the efficacy of
carbamazepine, for example, may
increase and follow-up of the
drug concentration during treat-
ment may be necessary. 
Right to supervised care
We are dealing with a long period
of treatment with several drugs,
all of which have their own ad-
verse effects. Irregular intake of
drugs and occasionally omitting
some drug will increase the risk
for development of drug resis-
tance significantly. The patient
will consequently need constant
support and motivation in order
to comply with a very demanding
therapy. The therapy should be
supervised if it appears that the
patient is unable to cope alone
with the treatment. Patient
groups in need of supervised ther-
apy include the elderly, individu-
als with memory problems, drug
and alcohol abusers, the socially
deprived, immigrants and individ-
uals with mental problems. 
The treatment is carried out in
outpatient care. Traditionally, the
carer’s responsibilities include
monitoring of adverse drug reac-
tions and also making sure that
the patient takes the dose pre-
scribed, but overall support to
the patient during the treatment
is the most important thing. The
patient’s life style, cultural back-
ground and language ought to be
considered. The patient decides
every day whether to take the
medication, and the use of intoxi-
cants and/or homelessness may
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Table 4. Recommendation for reintroducing tuberculosis medication after an interruption due to adverse reactions  
Adverse reaction 1. reintroduction1 2. reintroduction1 3. reintroduction1
Skin or fever reaction One drug at a time at intervals One drug at a time2 at intervals One drug at a time2 at intervals 
of 2–3 days, normal doses of 2–3 days, normal doses of 2–3 days, normal doses
Use of reaction-inducing drug Use of reaction-inducing drug Use of reaction-inducing drug 
is discontinued and is discontinued and is discontinued and
replaced by another drug. replaced by another drug. replaced by another drug.
Elevation of ALT or All drugs at the same time, One drug at a time2 at intervals of 5 days, Concomitant introduction of
bilirubin value normal doses. normal doses.3 INH + EMB, normal doses.
Thereafter, introduction of RMP 
and PZA with dose increments  
at intervals of 5 days.3
Use of reaction-inducing drug is 
discontinued and replaced by an
other drug.
1 Treatment may be continued once symptoms have been alleviated and laboratory values restored to normal. 
2 Introduction of treatment with a drug which is most likely to cause a reaction.
3 ALT and Bil x 2 / week at reintroduction.
pose another challenge in the
management of treatment. It is
important for the carer or any
other person supervising the
treatment that sufficient time
should be devoted to these re-
sponsibilities and that a network
of co-operation should be created
with those involved in specialised
nursing care, and that clear in-
structions for solving problem
situations should be agreed up-
on.  
Caution required on discontin-
uation of treatment
When the physician decides to
discontinue the patient’s treat-
ment, he makes sure that the du-
ration of the patient’s medication
has been adequately long (Tables
1 and 5). Any treatment intervals
will be deducted from the total
duration of treatment. If any of
the three primary drugs (isoni-
azide, rifampicin, pyrazinamide)
has been withdrawn due to ad-
verse reactions, the duration of
the treatment is prolonged corre-
spondingly in accordance with
Table 5. If after two months of
treatment sputum culture still re-
mains positive and cavities or
other changes have been found in
abundance on pulmonary X-ray
at the initial stage, then the dura-
tion of treatment should be pro-
longed up to 9 months.  
Follow-up monitoring is usu-
ally not necessary if, in the main,
no complications have occurred
during the treatment. Monitoring
at half-yearly intervals for 6
months to 2 years is recommend-
ed if an abundance of changes re-
main on pulmonary X-ray, or if
the patient’s lifestyle is such that
a new infection is possible.
Monitoring the end result
In accordance with the criteria
recommended by the WHO, the
end result of treatment of tuber-
culosis can be divided into seven
different categories  (healed,
treatment completed, unsuccess-
ful treatment, patient died, inter-
rupted treatment, patient trans-
ferred, treatment continues) (2).
The end result is assessed at the
latest a year after initiation of
treatment. The end result first
achieved is recorded. Several Eu-
ropean countries already have in
use a monitoring system of end
results. Its introduction is also
planned in Finland as part of the
recording system for National in-
fectious disease register. The
monitoring allows comparison of
end results in tuberculosis treat-
ment internationally, while im-
portant data are obtained for na-
tional development purposes. 
New drugs and methods of
administration?
New drugs and drug combina-
tions for the treatment of tuber-
culosis are constantly being stud-
ied and developed. A significant
step forward in pharmacotherapy
is expected within the next
decade. The aims include a short-
er duration of treatment and less
frequent dosages in order to im-
prove treatment compliance, and
development of drugs with an ef-
fect on treatment-resistant My-
cobacterium tuberculosis strains.
New methods of administration
such as inhalation are also under
development. Various immuno-
therapies such as interferon-gam-
ma inhalation and TNF blockers
have been tried, with no break-
through so far.
In conclusion
At its best, the treatment of tu-
berculosis consists of interesting
team work, in which the attend-
ing physician carries an impor-
tant responsibility to initiate and
maintain progress. The best end
result is achieved when both the
patient and the care personnel
are committed to the treatment
and monitoring.
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Table 5. Medication and duration of treatment if adverse reactions prevent the use of any pri-
mary drug   
Drug omitted Initial treatment Follow-up treatment Duration of 
treatment
PZA INH, RIF, EMB 2 months INH, RIF 7 months 9 months
RIF INH, PZA, EMB 2 months INH, EMB 10–16 months 12–18 months
INH RIF, PZA, EMB 2 months RIF, EMB 10 months 12 months
INH = isoniazide, RIF = rifampicin, PZA = pyrazinamide, EMB = ethambutol
Many studies have shown that
paediatric pharmaceutical thera-
pies lack adequate research data
respecting their efficacy, safety
and quality. The number of dif-
ferent pharmaceutical formula-
tions suitable for the various age
groups of children is also inade-
quate. In the EU, about half the
medicinal products used in chil-
dren do not have a marketing au-
thorisation for paediatric use.
This is a problem with both new
and old medicinal products, both
in developed countries and else-
where. Globally the shortcoming
in paediatric medicinal products
is especially acute with respect to
pharmaceutical formulations
which tolerate transport and stor-
age in a warm and humid atmos-
phere.
The industry has taken care to
develop some of the pharmaceuti-
cal formulations for children at
pre-school age and older, but
there are very few innovations
designed for the medication of
newborn and premature infants,
and knowledge about these par-
ticular pharmaceutical formula-
tions is scarce.
The problem with paediatric
medicinal products is recognised
in the USA and the EU where leg-
islative measures have been taken
to promote development and re-
search in the area. EU Paediatric
Medicinal Products Regulation
came into force on 26.1.2007
with the aim of improving the
health of children by increasing
the quantity of medicinal prod-
ucts intended for paediatric use
and of expanding the selection of
products meeting their needs. The
Regulation requires that when
applying for a marketing authori-
sation the pharmaceutical compa-
nies should also show the results
of drug trials carried out in chil-
dren, including development
work relating to pharmaceutical
formulations meeting the needs of
various age groups.
While the Regulation is being
enforced, the need for research
into pharmaceutical formulations
tailored for children will grow.
New approaches are, in fact,
needed in order to solve the prob-
lems of paediatric medication.
One example would be to devel-
op further a pharmaceutical for-
mulation for a medicine with
poor solubility in water in order
to make its administration to
children easy and accurate. En-
suring the stability of medicinal
products in liquid form and taste
masking their possible bad taste
would be other examples of
where development is needed.
The problems start with raw
materials
The impurities of raw materials
used in the medicinal products
may in fact be a problem in their
development for paediatric use.
For example, even if residues of
impurities, e.g. solvents such as
toluene were within recognised
limits and not posing any danger
to adults, they may actually be
harmful to children. Medicinal
substances may possibly also con-
tain impurities such as residues of
the parent substance which are
harmless to adults, but are ex-
tremely harmful to newborn and
premature infants. 
Excipients as such may pose a
problem. Owing to their poor
solubility, bad taste or poor com-
pressibility of drug substance,
medicinal products often need ex-
cipients with special properties
making handling easier. It may,
however, happen that these excip-
ients have toxic or other proper-
ties harmful especially to new-
born and premature infants. Ex-
amples include sweeteners such as
fructose, saccharose or saccharine
and glucose syrups, inappropriate
for patients with diabetes or fruc-
tose intolerance and associated
with a risk of causing osmotic 
diarrhoea similar to that with
sorbitol in small children. Preser-
vatives are another risky group of
excipients, including benzyl alco-
hol, which in sodium chloride so-
lution caused 10 deaths world-
wide in 1982. Benzoic acid and
its salts may cause jaundice in the
newborn. 
Parabens may disturb bilirubin
binding and cause allergies. The
number of medicinal substances
with poor solubility in water is
growing, and consequently the
use of various co-solvents and
surface active substances is also
growing. Even ethanol in surpris-
ingly high volumes is contained
in medicinal products for paedi-
atric use. Propylene glycol, for
example, is not recommended for
use in children under 4 years of
age due to its harmful CNS ef-
fects in large amounts in the new-
born. Surfactants such as poly-
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Special challenges involved with regard to 
medicinal products appropriate for children
oxyethylated castor oil may
cause anaphylactic shock. Fatal
cases have been associated with
the intravenous use of polysor-
bates in the underweight new-
born. Overall, the number of safe
excipients is relatively small, and
this makes careful planning nec-
essary in their choice and in the
choice of their distributors with
regard to product development in
the industry and the pharmacies.
Innovative pharmaceutical
formulations for children
Reforms in the legislation in the
USA have led to an increase in
the development of pharmaceuti-
cal formulations for children for
the purpose of clinical studies
and to their introduction on to
the market. Most of the medici-
nal products introduced on to
the market are, however, intend-
ed for children of pre-school age
or older and for adolescents.
Small technology companies have
emerged offering various solu-
tions to paediatric pharmaceuti-
cal therapies. An example of in-
novative solutions of this type is
that of a clarithromycin straw by
the German company Grünen-
thal allowing the medicinal gran-
ules to be packed in a straw and
thereby improving the ease of use
for the small patient when the
granules can be sucked in in
combination with a favourite
drink. Fentanyl, a lollipop in its
pharmaceutical form, or as tech-
nically known an integrated oro-
mucosal applicator, is already al-
so in use for pain relief in Fin-
land. For the treatment of older
children, intraoral pharmaceuti-
cal forms are used, such as poly-
mer membranes soluble in the
mouth, or soluble tablets. An in-
novation by the Danish company
Egalet, consisting of a medicinal
substance already dispensed in a
spoon, has reached its conceptual
stage. Nearly all of the above in-
novations are intended for chil-
dren of pre-school age and older,
who are commercially more prof-
itable targets for pharmaceutical
development. There are fewer in-
novative solutions available for
the medication of newborn and
premature infants.
Difficulty in taste masking
The bad taste of a medicinal sub-
stance in the oral pharmaceutical
formulations such as solutions,
suspensions and forms soluble in
the mouth is often a problem for
children. The taste of the product
should not be too bitter, gritty or
irritating. Masking the taste with
a flavour constitutes a challeng-
ing exercise, as the medicinal
substance may sometimes be bit-
ter to the extent that even in
small amounts it evokes a vomit-
ing reflex. If, in addition to a bad
taste, the substance also has a
bad smell, trying to make it
pleasant to use is a real chal-
lenge. A salty taste in a substance
is easier to cover with flavours
than a bitter taste. The physiolo-
gy of a taste also makes the cov-
ering of it difficult. One would
need to succeed in covering both
the initial stages of the taste (the
first 10 to 20 seconds) and the
after-taste (1 to 10 minutes). This
is rarely successfully done with
only one flavour. There are also
cultural differences in taste pref-
erences; berry flavours such as
cherry are popular in some coun-
tries, whereas sweet vanilla and
tutti-frutti are desired flavours in
others.
Another solution, but one of-
ten more costly, is to coat the
medicinal substance with a poly-
mer film which will not become
soluble until it reaches the acid
pH of the stomach. In that case,
it should be possible to divide the
substance into solid units: mini-
tablets, granules or pellets, which
can be coated without any prob-
lem. A frequent challenge in the
coating is that it should cover the
products as well as possible.
Even a small crack in the film
may cause the medicinal sub-
stance to become soluble in the
oral fluids.
Improving dosage
Children in hospitals and outpa-
tient care are in practice given a
lot of medicinal products which
have not been registered for pae-
diatric use, or an appropriate
medicinal product is not avail-
able on the Finnish market. The
products are often manufactured
ex tempore from the adult prod-
ucts into metered dose powders,
capsules or suspensions, and this
may cause problems both in the
shelf-life of the product in a liq-
uid form and in the dosage. The
unsuitable dosage alternative is
halving a non-scored tablet
which may result in a situation
where a child receives anything
between 50 and 150 % of the in-
tended dose. From the point of
view of dosing, liquid prepara-
tions, solutions and suspensions
are usually better as to their flex-
ibility and accuracy. All medici-
nal substances cannot, however,
be made into liquid preparations
because of the difficulty of stor-
age. Then we have to concentrate
on novel innovations such as
granules, pellets and other small
solid pharmaceutical formulation
with flexible but accurate admin-
istration.
An optimal medicinal product
for paediatric use comprises ex-
cipients appropriate for children:
it tastes good and can be readily
administered orally, making the
individual dosage easy. The ab-
solute requirement is that the
chemical and microbiological
shelf-life of the product should
be good in all climate zones of
the world. The pharmaceutical
formulation should also be cost-
effective to manufacture. To
solve the above challenges by
economically viable means is a
real problem for the pharmaceu-
tical industry and a challenge of-
fering scope for many new inno-
vations both in companies and at
universities.
See literature on page 44.
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Our review covers adverse drug
reactions (ADRs) caused by con-
ventional drugs in children. Vac-
cines are excluded from the re-
view. The ADR register of NAM
has since 1973 received a total of
1,203 reports of adverse effects
discovered in children, 0 to 15
years of age. The number of re-
ports in this age group annually
has varied between 24 and 69
since the start of the 1990s (Fig.
1). The proportion of serious
ADRs over this timespan has var-
ied between 18% and 63% of the
reports. 
In the review we have includ-
ed the reports where the age of
the child involved in the ADR in-
cident is included. The majority
of the reports are on the smallest
children, the 1 to 2-year-olds
(Fig. 2). The majority of the
ADRs involving this age group
have been caused by anti-infec-
tives for systemic use, and this
probably reflects the use of an-
tibiotics in that age group. Re-
ported reactions in boys (53%)
slightly exceeded those in girls
(47%).
Among the various drug
groups the highest number of re-
ports have been received on anti-
infectives for systemic use (612 in
total), drugs affecting the nervous
system (254) and drugs affecting
the respiratory system (103). The
reports, divided into drug groups,
are shown in the Table.
Among the anti-infectives for
systemic use, the drugs most fre-
Fig. 1. All ADR reports 1973–2006.
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Fig. 2. ADR reports in children age of  0–15 years 
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quently reported on included ce-
faclor (137 reports), amoxicillin
(133), sulfamethoxazole-
trimethoprim combination (54)
and penicillin V (51). Skin was
the target of 120 reactions
caused by cefaclor, and the reac-
tion almost without exception
was urticaria with associated
joint symptoms. Serum sickness
was the actual diagnosis in 10
cases. 
Of the reports on amoxicillin,
107 described various rashes,
generally the ADR consisted of
only rash or urticaria, while oc-
casionally other symptoms were
reported such as fever or arthri-
tis. Serum sickness was men-
tioned in three and erythema
multiforme in two reports. Bow-
el symptoms were a subject of
20 reports, 15 of which involved
as the adverse reaction melaena
or some other bowel haemor-
rhage, and the others included
pseudomembranous enterocoli-
tis / Clostridium difficile (3), col-
itis (1) and diarrhoea (1). The
ADRs of penicillin V were simi-
lar to those of amoxicillin, but
reports of actual serum sickness
totalled 11.
Forty-four of the ADRs
caused by sulfamethoxazole-
trimethoprim included various
rashes, the diagnosis in five cases
being the Stevens-Johnson syn-
drome. Nine reports described a
reduction in the leukocyte level.
The majority (22) of reports
concerning sulfadiazine-
trimethoprime (27 in total) de-
scribed various harmful skin ef-
fects; there were 4 reports each
of epidermal necrolysis and of
the Stevens-Johnson syndrome. 
The largest group of medici-
nal substances affecting the ner-
vous system consisted of
antiepileptics. There were 40 re-
ports on carbamazepine, 36 on
oxcarbazepine, 22 on valproic
acid and 15 on vigabatrin.
Twenty-nine of the reports on
carbamazepine involved skin
symptoms, and hepatic reactions
and leukocyte level reduction
were each reported on four oc-
casions. Following the 18 skin re-
actions caused by oxcarbazepine
the most frequently reported ad-
verse reaction alone was 4 from
hyponatraemia. The most fre-
quently reported ADRs caused
by valproic acid were the 7 tar-
geted at the liver and those by vi-
gabatrine the 10 targeted at the
visual field.
A total of 24 reports were re-
ceived on various local anaesthet-
ics, most frequently on combina-
tion therapies containing either
lidocaine or articaine (7 reports
on each). The ADRs mainly con-
sisted of various hypersensitivity
reactions and nausea.
In the group of drugs used for
respiratory system diseases the
one that stood out was mon-
telukast, with 16 reports re-
ceived. Nine of these described
adverse effects on the central ner-
vous system and the psyche (agi-
tation, muscle stiffness, aggres-
sive reaction, sleep disturbances
including nightmares and night
terror attacks, headache). There
were 2 reports on skin reactions,
and other isolated adverse reac-
tions included vomiting, nose-
bleed, dyspnoea associated with
urticaria, QT interval prolonga-
tion and elevated liver enzyme
values.
The above-mentioned central
nervous system and psychic
symptoms were of the kind men-
tioned in the SPC of Singulair.
These adverse drug reactions
may in fact be significant; for ex-
ample, there was one case of a 7-
year-old boy who was afraid of
going to school due to his panic
attacks. A week after discontinu-
ation of the medication, the child
was symptomfree.
Figure 3 shows all the reports
according to the system organ
class of the most significant
ADR. The majority of the re-
ports (46%) described adverse
skin effects, followed by effects
on the alimentary tract (11%),
general adverse reactions (6%),
effects on the nervous system
(5%) and the immune system
(5%). General adverse reactions
also included local reactions as-
sociated with the method of ad-
ministration, fever and various
types of oedema and effects on
the immune system, including
various allergic reactions, such
as anaphylaxis and serum sick-
ness.
Reports of adverse drug reactions in children since 1973 lined up  by
drug groups 
Number of reports
Anti-infectives for systemic use 612
Drugs affecting the nervous system 254
Drugs affecting the respiratory system 103
Drugs affecting the alimentary tract and metabolism 75
Antineoplastic and immunomodulating agents 26
Other drugs 25
Drugs affecting the musculoskeletal system 18
Dermatologicals 17
Drugs affecting the genito urinary system and sex hormones 17
Systemic hormonal preparations (excl. sex hormones and insulins) 16
Drugs affecting the blood and blood-forming organs 12
Drugs affecting the sensory organs 12
Antiparasitic products, insecticides and repellants 9
Drugs affecting the cardiovascular system 7
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The spectrum of adverse reac-
tions in children starts with prob-
lems associated with neonates’
drug exposure during pregnancy
and ends up with reactions
emerging at the threshold of
adulthood, which could be asso-
ciated, for example, with the use
of isotretinoin or contraceptives. 
Paediatric case reports
Due to a panic disorder a female
had been using essitalopram
throughout her pregnancy. Her
newborn baby was initially sleepy
and did not eat well, but ulti-
mately recovered from the symp-
toms. Symptoms in the newborn
exposed to SSRI drugs during the
final stages of pregnancy can be
varied (including irritability,
seizures, tremor, difficulties in
breathing) and are the results of
either the serotonergic effects of
the drug or withdrawal symp-
toms associated with the discon-
tinuation of the medication.
A 3-year-old girl was started
on cetirizine therapy for allergic
symptoms of the eye with a daily
dose 5 mg. The following day the
girl started to stutter. The therapy
was discontinued and the child
recovered. No such symptom oc-
curred with the use of loratadine.
In connection with the use of cet-
irizine, this is the only report of
its kind in the ADR Register.
A 4-year-old boy was in inten-
sive care due to tracheal surgery,
and the sedatives used included
oxicone and midazolam. About a
week after surgery tropisetron 2
mg was administered intra-
venously for nausea. A couple of
hours afterwards the child be-
came restless and suffered from
involuntary movements of the
hands, which could well be inter-
preted as extrapyramidal symp-
toms. As the symptoms were pro-
longed, suspicion rose about the
unusual metabolism of tro-
pisetron. Tropisetron is metabol-
ised via the CYP2D6 enzyme,
which in this child had slow
metabolic action, a condition
found in 5 to 10% of whites. The
symptoms were alleviated by
biperiden therapy, and once this
had been gradually withdrawn
the child was totally symptom-
free.
A 5-year-old girl weighing 18 kg
and suffering from rheumatoid
arthritis was given scopolamine
eye drops for the treatment of iri-
tis (inflammation of the iris); the
drops had been administered
twice. The girl started swaying
while walking and she fell; after
which the girl became over-excit-
ed, did not sleep for 36 hours,
played and talked constantly and
had hallucinations. She was also
sweating and suffering from
tachycardia. Following discontin-
uation of her medication, the girl
recovered from the symptoms,
which were of a type which could
have been caused by scopo-
lamine.
A 6-year-old girl experienced
(unspecified) extrapyramidal
symptoms and an oculogyric cri-
sis (involuntary turning of the eye
balls, usually upwards) 2 days af-
ter the introduction of metoclo-
pramide therapy (30 mg/day). She
recovered once the medication
was discontinued. Extrapyrami-
dal symptoms are known adverse
reactions associated with meto-
clopramide dopamine antago-
nism. Dystonic reactions such as
oculogyric crisis, torticollis and
Gastrointestinal disorders
11 %
General disorders and administration site
conditions
6 %
Nervous system disorders
5 %
Immune system disorders
5 %
Blood and lymphatic system disorders
4 %
Psychiatric disorders
4 %
Investigations
4 %
Respiratory, thoracic and mediastinal disorders
3 %
Other disorders
12 %
Skin & subcutaneous tissue disorders
46 %
Fig. 3. Reported adverse drug reactions according to SOCs .
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trismus, occur in children in par-
ticular and may even develop fol-
lowing the first single dose.
A 7-year-old boy was admit-
ted to hospital due to vomiting
and shifting levels of conscious-
ness (motor movements similar
to those of a drunkard, with
rolling eyes, unclear speech, need
to be supported on arrival to
hospital, opened eyes when
prompted, did not speak). A
computer tomography of the
head and a cerebrospinal fluid
examination did not reveal any-
thing abnormal, but serum am-
monia and aminotransferase lev-
els were clearly elevated. Two
days afterwards mild unspecific
changes were detected on elec-
troencephalography (EEG). In
follow-up, ammonia and amino-
transferase values started on a
downward trend and conscious-
ness returned to normal. It be-
came clear that during the week
prior to admission to hospital the
child had been receiving acetyl-
salicylic acid for three days due
to a virus infection. He was diag-
nosed as suffering from Reye’s
syndrome, a severe disease of un-
known aetiology which causes
damage to the brain and liver. It
is a rare disease, manifested pre-
dominantly in children. Reye’s
syndrome has been linked with
the use of acetylsalicylic acid
during infections, which is why
some other preparation should
be chosen for fever therapy in
children and adolescents.
A 10-year-old girl received a
five-day course of treatment with
sulfadiazine-trimethoprim. On
the second day after discontinua-
tion of the medication, a toxic
epidermal necrolysis (extensive
scaling of the skin) developed.
There were no more details avail-
able about treatments, and the
child had not yet recovered at the
time of reporting (12 days after
the emergence of the symptoms).
A toxic epidermal necrolysis may
as a rare ADR be associated with
both sulphonamides and
trimethoprim and is life-threaten-
ing similarly to an extensive
burn, because the patient is ex-
posed to disturbances in the fluid
balance and temperature control
as well as to severe infections.
A 12-year-old boy had re-
ceived citalopram 20 mg daily
for about three months, when a
rash of the erythema fixum type
developed in the little finger. The
change in the skin disappeared
after discontinuation of the med-
ication, and there is no knowl-
edge about re-exposure. Erythe-
ma fixum (fixed drug eruption)
is always caused by a drug, e.g.
doxycycline, a sulphonamide or
carbamazepine. With re-exposure
a change in the skin always ap-
pears on the same spot as before
and heals within a couple of
days, followed by a pigmentation
left in the skin. In addition to the
“old” spots, a drug re-exposure
may expand the skin syndrome.
Consequently, the patient should
not be re-exposed to the
causative agent once the diagno-
sis is confirmed.
A 14-year-old boy, who, fol-
lowing a 4-month course of
olanzapine (dose increased grad-
ually up to the level of 20 mg
daily), was diagnosed as having a
slightly elevated level of serum
alanine aminotransferase. An ul-
trasound examination of the up-
per abdomen was carried out,
the finding of which fitted in
well with a fatty liver. During
olanzapine therapy the patient
had gained weight by about 40
kg. Weight gain is a common ad-
verse reaction associated with
olanzapine and it may be associ-
ated with the development of a
fatty liver as was the case with
this patient. Olanzapine may al-
so for other reasons cause eleva-
tion of aminotransferases.
A 15-year-old boy with can-
cer was initially treated with in-
travenous metronidazol 1 g
about midday, followed by clin-
damycin 600 mg about three
hours afterwards. The boy devel-
oped an antabus type of reaction
(palpitations, hypotension, cold
sweat, pallor) during the clin-
damycin infusion, which was
thought to have been caused by
the combination of benzyl alco-
hol, contained in the clindamycin
preparation, and metronidazole.
The boy was given intravenously
promethazine which relieved the
reaction. 
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A 16-year-old boy was admitted
to the central hospital emergency
unit on a referral from a doctor
at a health care centre, the cause
being tiredness and forgetfulness.
The patient did not have any his-
tory of psychiatric illnesses or of
intoxicants abuse as far as we
know. Earlier in the same year he
had been examined at the paedi-
atric ward for reduced growth
rate and delayed puberty. At the
age of 12 he had been examined
in the paediatric neurology unit
for delayed development and
learning difficulties. Owing to
borderline mental retardation he
had attended comprehensive
school in the special needs teach-
ing unit. At the age of 14 he had
fallen on his bicycle with a resul-
tant fracture of the right tempo-
ral bone and evidently also a mi-
nor left-sided subarachnoid
haemorrhage. 
A week before admission to
the emergency clinic the patient
had started a course of cephalex-
in at a dose of 750 mg twice dai-
ly for the treatment of a nail
fringe inflammation. According
to the description by the parents,
following the introduction of the
medication the patient had be-
come weary and forgetful, and
tended to stare and look vacant.
In many situations, impairment
of the patient’s immediate memo-
ry became evident. He had, for
example, lost his goods and sus-
pected others of having stolen
them. Furthermore, he had not
slept well for some time. For the
24 hours prior to admission to
hospital he was described as hav-
ing been tired, confused and dis-
orientated.
When interviewed at the
emergency clinic the patient did
not say much and hardly had any
eye contact. He delayed replying
to many questions and on occa-
sion it appeared as if he had not
heard the question at all, but
stared in front of him deep in his
own thoughts. The boy main-
tained that sounds (e.g. the TV)
disturbed him, but he denied
having any hallucinations. He al-
so said he had recently wanted
mostly to be alone and to rumi-
nate over his own affairs, and
that there were things ‘you
should not talk to anybody
about’. Mild motor restlessness
and tearfulness also emerged dur-
ing the interview.
The patient had no symptoms
of infections. A somatic examina-
tion and laboratory tests did not
reveal any cause explaining the
delirium. B-Hb was on the low
side: 130, B leucocytes 7.4, plas-
ma potassium 4.1, plasma sodi-
um 141, CRP < 1, plasma glu-
cose 5.4, intoxicants screening of
the urine was negative. EEG was
normal.
Owing to suspected psychosis
it was decided to admit the pa-
tient to the adolescent psychiatric
ward for a more close assessment
of his condition, and the cephal-
exin therapy was discontinued.
The boy quickly started to feel
better on the ward to the extent
that all symptoms indicative of
delirium or psychosis disappear-
ed within two days. He was still
monitored on the ward for a
couple of days, was discharged
thereafter and was immediately
able to start his studies at a voca-
tional school. During the 7-
month follow-up period the pa-
tient’s condition has remained
good.
Conclusion
Cephalosporins are widely used
for the treatment of various types
of infections and are usually well
tolerated as a medication. It ap-
pears, however, that they may in
some patients cause significant
central nervous system effects.
The probable factors which
could have exposed the patient I
have described to CNS effects of
medicines include a young age,
delayed neurological develop-
ment and a history of a skull-
brain injury (1). Korn et al. (2)
have presented study results
showing that even a relatively
mild head injury may impair the
blood-brain barrier function even
for years, which is likely to facili-
tate the penetration of medicinal
substances into the brain tissue.
In the literature, at least two
previous descriptions of states of
delirium during cephalexin thera-
py in adult patients can be found
(3, 4) and also several observa-
tions of a similar type associated
with the use of other cephalo-
sporins (5). In the ADR database
in Finland, in addition to my pa-
tient’s case, there are nineteen re-
ports made of cephalosporins
psychiatric and nervous disorders
(Kari Salmela, National Agency
for Medicines). 
See literature on page 48.
Own observation of an adverse reaction
Delirium in an adolescent patient with the use of
cephalexin 
Jani Penttilä
Specialist in Adolescent Psychiatry , Senior Researcher
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Use of antipsychotics in outpatient care in 2005
According to a recent survey (1),
the lifetime prevalence of all psy-
chotic disorders in the Finns is
3.5%, and the most common dis-
order is schizophrenia. The treat-
ment of psychotic disorders in-
cludes both conventional and
more recently introduced anti-
psychotics. Second-generation
antipsychotics have become more
generally used during the last
decade: only about a fifth of the
total consumption of antipsy-
chotics in 1998 were of the sec-
ond-generation, whereas in 2005
they already accounted for two-
thirds of the consumption. The
costs of antipsychotics have more
than tripled over the same time
span. As the consumption mea-
sured in drug doses has increased
in this period by only about
20%, the main cause for the in-
crease in costs is the higher cost
of the new drugs (2).
Reimbursements to cover the
cost of antipsychotics consist of
both basic and special refunds. In
2005 the patient only paid five
euros per purchase transaction
for drugs covered by a higher
special refund entitlement, but
the special refund entitlement for
antipsychotics (code 112) was re-
served for patients with a severe
psychosis or other severe mental
health disorders. 
The proportion of the anti-
psychotics consumed in outpa-
tient care has grown steadily and
reached 83% in 2005 (3, 4). In
the same year the Social Insur-
ance Institution (SII) paid out re-
funds for antipsychotics (N05A)
to 116,634 patients in total,
63,166 (54%) of whom were en-
titled to a special refund.
This study surveyed the use of
antipsychotics in outpatient care
as well as at the distribution of
use and cost by age, sex, mother
tongue and domicile in 2005.
Subjects with special refund enti-
tlement of antipsychotics were
distinguished from those who
had purchased antipsychotics
without special refund entitle-
ment.
Subject data and methods
The subject data were picked
from the prescription records and
the database of special refund en-
titlement of SII and the statistics
produced by Statistics Finland as
described earlier (5). From the
original sample, i.e. a 50% sam-
ple of subjects using antipsy-
chotics in 2005, those subjects
were selected who had been re-
funded for the cost of their drugs
in ATC group N05A.
Subjects were excluded from
this study if they had no other
purchases of the N05A group
drugs than lithium, prochlorper-
azine or dixyrazine, if their spe-
cial refund entitlement 112 was
valid only part of or before the
year 2005, or if they had special
refund entitlements associated
with delayed mental develop-
ment, neuralgia or epilepsy.
The final subject material con-
sisted of 47,503 individuals, of
whom 27,756 (58%) had a valid
special refund entitlement 112
throughout the year. The rest of
the subjects, 19,747 (42%) had
never been a holder of special re-
fund entitlement 112. Of the to-
tal antipsychotics consumed
among the subjects, 90% was
covered by a special refund.
Results
Women made up 54% of those
using antipsychotics with a spe-
cial refund entitlement, but the
majority of the under 55-year-
olds were men. The average age
of men was 48 years (the same
figure being the median), and of
women 54 years (idem). Judged
by this subject material, the pro-
portion of those using antipsy-
chotics with a special refund enti-
tlement in 2005 was highest
among men of ages 45 to 59
(2.0% of the age group) and
among women of 50 to 69
(2.4% of the age group).
Of those using antipsychotics
with a basic refund entitlement
56% were women; while in the
age groups below 75 years the
majority were men. The average
age of the men was 55 years (me-
dian of 56 years), and that of the
women 64 years (median of 70
years). Judged by this subject ma-
terial, the proportion of those us-
ing antipsychotics with only ba-
sic refunds in 2005 was highest
in the age group of 90 to 94
years in both men (6.7% of the
age group) and women (7.1% of
the age group).
Drug use
Of those entitled to a special re-
fund, 31% had during the year
of the survey used only conven-
tional antipsychotics, 49% had
used only new-generation drugs,
and 20% had used both. The
more recent the entitlement to a
special refund, the higher the
proportion of users of the new-
generation drugs.
During the year of the survey,
among those using antipsychotics
without special refund entitle-
ment, 43% had used only con-
ventional antipsychotics, 52%
had used only new-generation
drugs, and 5% had used both.
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The majority of the middle-aged
subjects had used only conven-
tional antipsychotics, whereas
the majority of under 35-year-
olds and the over 74-year-olds
had used only the more recent
antipsychotics.
Fifty-one percent of adoles-
cents and working age adults
(the 15- to 64-year-olds) entitled
to special refunds had been using
only new-generation antipsy-
chotics as were 43% of adoles-
cents and working age adults
without special refund entitle-
ment. Conventional antipsy-
chotics alone were used by 27%
of those with a special refund en-
titlement and 51% of those who
received only basic refunds. The
differences between the sexes in
this age group were not statisti-
cally significant. 
The antipsychotics most com-
monly used by those entitled to
special refunds included olanzap-
ine, risperidone and quetiapine.
Antipsychotic-users with a basic
refund entitlement were most fre-
quently using risperidone, queti-
apine and levomepromazine.
Olanzapine, perphenazine, lev-
omepromazine, clozapine, chlor-
prothixene, thioridazine, zuclo-
penthixol and chlorpromazine
had been used by a greater num-
ber of those with entitlement to a
special refund than those with
entitlement to a basic refund;
risperidone, quetiapine, haloperi-
dol and melperone were more
commonly used by those receiv-
ing only basic refunds rather
than those with special refund
entitlement.
Those entitled to special re-
funds had during the year used
on average about 1.5 antipsy-
chotics, and those receiving only
basic refunds on average about
1.1, irrespective of sex. Among
those with a special refund enti-
tlement, 63% (61% of men,
65% of women) had during the
year received refunds for only
one antipsychotic, 90% for two
at the most. Of those not entitled
to special refunds, 90% had re-
ceived refunds for one antipsy-
chotic alone.
Drug costs
In this subject material, 93% of
the costs of the antipsychotics
were incurred by the new-genera-
tion drugs. There were great in-
dividual variations in the annual
costs of these drugs, depending
on the refund group, sex and the
type of drug used (Table). The
average costs of antipsychotics
used by men were without excep-
tion slightly higher compared
with those used by women. The
costs of antipsychotics used by
those entitled to a special refund
were on average 5 to 6 times
higher compared with those
without special refund entitle-
ment.
Compared with those who
had used conventional antipsy-
chotics alone, the drug costs for
those who had used only new-
generation antipsychotics were
on average 8 to 10-fold as high,
and the costs for those having
used both types of drugs were 12
to 13-fold.
Discussion
The growth and qualitative
change of antipsychotics con-
sumption may partly be ex-
plained by the wider spectrum of
effect and improved tolerability
of the new-generation drugs
compared with the conventional
ones. The conventional antipsy-
chotics are nevertheless cost-ef-
fective and do have an effect on
positive symptoms. Perphenazine
especially has been successfully
used in the treatment of schizo-
phrenia in the more recent con-
trol studies (6, 7). Nevertheless,
conventional antipsychotics have
many adverse effects, and the so-
called high-dose neuroleptics
(chlorpromazine, chlorprothix-
ene, levomepromazine, prom-
azine and thioridazine), in partic-
ular, have had serious, even fatal
toxic effects. The reduced use of
conventional antipsychotics is ac-
tually also evident in the fact that
deaths caused by antipsychotics
intoxication have been halved be-
tween the years 2000 and 2004
(8, 9).
Tabell. Average costs of antipsychotics by the subjects in the survey material in 2005.
Those with special refund entitlement Those with basic refund entitlement
Cost (€) and Excess paid by  Cost (€) and Excess paid by 
refund percentage the patient (€) refund percentage the patient (€)  
Those having used 
only conventional 
antipsychotics
Men 186 (91%) 18 47 (39%) 29
Women 145 (89%) 17 42 (39%) 25
Those having used 
only new-generation 
antipsychotics
Men 1 743 (98%) 33 374 (60%) 149
Women 1 501 (98%) 30 352 (61%) 137
Those having used 
both conventional 
and new-generation 
antipsychotics
Men 2 176 (98%) 42 627 (66%) 217
Women 1 858 (98%) 40 493 (65%) 171
Another factor to explain the
increased total consumption of
antipsychotics is the steady in-
crease in the numbers of special
refund entitlement during the en-
tire first half of the 2000s; that
is, compared with the year 2000,
in 2005 there were 16% more
holders of the entitlement 112.
This increase is partly due to the
aging of the population, since the
proportion of the over 55-year-
olds grew by 14% (from 26% to
30%) over the same period,
while the proportion of those en-
titled to a special refund for an-
tipsychotics is growing with age;
in 2005, 2.9% of the over 55-
year-olds were holders of entitle-
ment 112, as were 1.2% of the
under 55-year-olds (10).
This survey indicates that
those using antipsychotics with-
out special refund entitlement are
on average older than those with
a special refund entitlement; in
2005, over a third of those using
antipsychotics without special re-
fund entitlement were 75 years
of age and older. The use of psy-
chotropics among the elderly
without special refund entitle-
ment has been discussed in detail
in a separate review (5).
With regard to the refund
group and the first year of enti-
tlement to a special refund, dis-
tinct differences were seen in
both the use of the first and sec-
ond-generation antipsychotics
and the use of individual medici-
nal substances. The number of
users of conventional antipsy-
chotics alone was higher among
those receiving only basic refunds
(43%) compared with those with
a special refund entitlement
(31%). This may be partly ex-
plained by the fact that, without
the entitlement to a special re-
fund, the drug costs born by the
patient are multiplied many times
over as a conventional drug is re-
placed by a new-generation drug,
whereas to a holder of a special
refund entitlement the annual ex-
cess in euros actually has little
relevance (Table).
In the Finnish Current Care
guidelines for schizophrenia (11),
reference is made to the key im-
portance of avoiding adverse re-
actions in the pharmaceutical
treatment of psychoses. The rele-
vance of this is emphasised in the
treatment of the elderly, in partic-
ular (12). Over 60% of the elder-
ly who had used antipsychotics
without special refund entitle-
ment had in fact only used the
new-generation antipsychotics.
However, the proportion of those
using the new-generation antipsy-
chotics alone was highest among
the under 25-year-olds. It is in
fact considered that the second-
generation antipsychotics have
made it possible to start the treat-
ment of psychotic disorders in
young patients earlier than before
(12). 
According to the Current Care
guidelines (11), the use of the
more recent antipsychotics in the
treatment of first-episode psy-
choses is justified by the lower
number of neurological adverse
effects and a broader spectrum of
effect, even though conventional
antipsychotics are also still appro-
priate in the treatment of first-
episode psychoses and in particu-
lar for such patients who have
earlier benefited from these drugs.
In this subject material, the
longer the duration of the disease,
the more common was the use of
conventional antipsychotics by
the patient. It appears that the
recommendation for using an-
tipsychotics as a monotherapy is
also well adhered to (11), since in
2005 three quarters of the sub-
jects had received refunds relating
to one antipsychotic agent only.
Despite the high cost of the
new generation antipsychotics,
pharmaceutical therapy only ac-
counts for a small proportion of
the costs incurred to the society
by psychotic disorders, while oth-
er direct (institutional care, out-
patient rehabilitation) and indi-
rect (lost productivity, disability
pensions) costs make up the ma-
jor part (13). To counterbalance
the rise in the costs of drugs, con-
sideration should be given to the
progress introduced by the new
medicinal substances and phar-
maceutical forms in the treatment
of psychotic disorders.
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